TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03897127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~* Patients age 18-60 years~  o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~* Patients age \>60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine \[65 U/m²\] i.v. (90 min) d1,3
Study: NCT00407082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide intravitreal implant
Description: Fluocinolone acetonide ocular implant 0.59mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 2.1mg
Description: Fluocinolone acetonide ocular implant 2.1mg
Study: NCT02342210

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
Description: MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
Description: MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
Study: NCT02909439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex will be given for reversal of neuromuscular blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine will be given for reversal of neuromuscular blockade.
Study: NCT00318019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OPC Factor(TM)
Description: Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
Study: NCT03284905

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: Capsule containing freeze dried probiotic bacteria together with maize starch
Study: NCT00681967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg; oral
Study: NCT02913352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet procedure
Description: Open anterior glenoid bone graft from coracoid process

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Eden-Hybinette
Description: Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
Study: NCT02074306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UROSHIELD®
Description: An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM UROSHIELD®
Description: SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
Study: NCT01557218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cucumber snack
Description: Three 300-g bowls of vegetables per table: three of cucumber slices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pepper snack
Description: Three 300-g bowls of vegetables per table: three of yellow pepper strips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato snack
Description: Three 300-g bowls of vegetables per table: three of grape tomatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable variety snack
Description: Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple snack
Description: Three 300-g bowls of fruits per table: three of apple wedges

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peach snack
Description: Three 300-g bowls of fruits per table: three of peach slices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pineapple snack
Description: Three 300-g bowls of fruits per table: three of pineapple half-rings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit variety snack
Description: Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
Study: NCT02176291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT03978624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV on day 1 and day 22
Study: NCT04223999

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Tumor treating fields combined with best medical treatment.
Study: NCT03144817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate Sodium Lowering
Description: Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
Study: NCT01000610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000 mg iv infusion on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25 mg weekly (oral or parenteral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 100 mg iv prior to each rituximab infusion
Study: NCT04297995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
Study: NCT03978624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV on day 1 and day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 5 mg given orally on day 1, day 8 and day 15
Study: NCT02723110

Intervention type: OTHER
Intervention: 4 Hour Frequently Sampled Oral Glucose Tolerance Test
Description: Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240

Intervention type: OTHER
Intervention: 4 Hour Frequently Sampled Oral Glucose Tolerance Test
Description: Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240

Intervention type: OTHER
Intervention: Isoglycaemic Clamp
Description: Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240

Intervention type: OTHER
Intervention: Isoglycaemic Clamp
Description: Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
Study: NCT04674618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US-assisted nusinersen administration
Description: Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04202653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV
Description: entecavir 0.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: entecavir 0.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: entecavir 0.5 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV
Description: entecavir 0.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: entecavir 0.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: entecavir 0.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 po qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 po qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 po qw
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03873844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block.
Study: NCT04202653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 po qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B2450
Description: TQ-B2450 q3w iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B2450
Description: TQ-B2450 q3w iv
Study: NCT00643487

Intervention type: PROCEDURE
Intervention: observation of the behavior of the infrapatellar plica
Description: Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
Study: NCT00755846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study: NCT00755846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT03604510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalographic recordings
Description: 24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
Study: NCT02678663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection-assisted Cold Snare Polypectomy
Description: Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: Resection of a polyp after blue-tinted saline injection using snare electrocautery
Study: NCT04297995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX10
Description: Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study: NCT03284905

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Capsule containing maize starch
Study: NCT03095521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angal, lozenges [menthol],
Description: Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTI-ANGIN® FORMULA
Description: 0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution.
Study: NCT04297995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
Study: NCT01496521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100mg qd for 6 months.
Study: NCT03414008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo: Tartaric acid
Description: Single dose
Study: NCT00383721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate MDI (MF MDI)
Description: MF 400 mcg via metered dose inhaler twice daily for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol MDI
Description: Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI twice a day for 26 weeks
Study: NCT03076190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational My Surgical Success Video
Description: The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
Study: NCT01496521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea Polyphenols
Description: 300mg bid for 6 months.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study: NCT04297995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX07 placebo
Description: HLX07 placebo 1000 mg every three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin/Carboplatin
Description: Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study: NCT04284904

Intervention type: DIAGNOSTIC_TEST
Intervention: aGVHD biomarker
Description: To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks

Intervention type: DIAGNOSTIC_TEST
Intervention: aGVHD biomarker
Description: To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks

Intervention type: DIAGNOSTIC_TEST
Intervention: aGVHD biomarker
Description: To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
Study: NCT00669916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: single infusion of 3 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single infusion of placebo
Study: NCT00910429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
Study: NCT00723411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
Study: NCT04293562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT03873844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transfer Package from CI Therapy
Description: Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
Study: NCT04299074

Intervention type: OTHER
Group type: OTHER
Intervention: addiction
Description: questionnaire
Study: NCT00723411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270